12.08.22 -- Advancing Pediatric Oncology Drug Development

A diagnosis of pediatric cancer can be a heartbreaking journey for children, families, and physicians. These trials involve the most vulnerable patients, and the experience will shape the rest of their lives. This article discusses what patient centricity means in these trial designs and how to create a more positive experience for patients and their caregivers.

Any health interaction with a child may be interpreted as invasive and stressful during a clinical trial. Learn about some of the important considerations for the family at the consent stage and issues that may arise during the trial itself.

Developers of oncology therapeutics are closely following the Research to Accelerate Cures and Equity for Children Act (also known as the RACE for Children Act). In this white paper, delve into a summary of the proposed legislation and potential impacts on oncology development programs if adopted.

Among all ongoing cancer trials, more than 70% involve RACE-defined molecular target drugs, but only 6.9% appear to include pediatric-age participants, according to a new analysis conducted by the IQVIA Institute. Read about the promising approaches with the RACE for Children’s Act implementation and how they will have a significant impact on cancer drug development.